Companies: 10,795·Total market cap: $144.5T
Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated

PRLDNASDAQHealthcare● Active
$3.84
+$0.03(+0.79%)
Market Cap$218621864
P/E Ratio—
52W High$5.54
52W Low$0.75
SEC Filings

Prelude Therapeutics Incorporated (PRLD) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001678660 · PRLD · NASDAQ · as of Jun 9, 2026

Filing snapshot

378
Total Filings
10-Q
Latest Form
2026-05-12
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001678660 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-10
Fiscal Year End
Mar 10, 2026
Accession No.
0001193125-26-099428
Primary Document
prld-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001678660 · Accession 0001193125-26-099428

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-12
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-12Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
10-Q
2026-05-12
View
8-KCurrent Report
8-K
2026-05-12
View
ARSARS
ARS
2026-04-29
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-29
View
DEF 14AProxy Statement
DEF 14A
2026-04-29
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-28
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-04-28
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-04-23
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-04-22
View
8-KCurrent Report
8-K
2026-04-21
View
424B5424B5
424B5
2026-04-21
View
8-KCurrent Report
8-K
2026-04-20
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-04-15
View
8-KCurrent Report
8-K
2026-04-15
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-03-19
View
Showing 1–15 of 222 filingsForm 4 / 144 hidden· 378 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001678660  |  Exchange: NASDAQ · Healthcare

Prelude Therapeutics Incorporated (NASDAQ: PRLD) has submitted 378 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001678660, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Prelude Therapeutics Incorporated's most comprehensive regulatory disclosure. The most recent Prelude Therapeutics Incorporated 10-K was filed on 2026-03-10 for fiscal year ending 2026. Historical PRLD 10-K annual reports are available from 2016 through 2026.

Investors researching Prelude Therapeutics Incorporated SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
ENTA SEC Filings →OBIO SEC Filings →FHTX SEC Filings →IVA SEC Filings →EPRX SEC Filings →CRBU SEC Filings →AVTX SEC Filings →IMRX SEC Filings →
→ PRLD Financials→ PRLD Earnings→ PRLD Insider Trades

Frequently Asked Questions

PRLD SEC Filings · 8 questions

Prelude Therapeutics Incorporated (PRLD) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 378 filings and access original documents at no cost. Prelude Therapeutics Incorporated's CIK is 0001678660.

PRLD SEC filingsPrelude Therapeutics Incorporated SEC documentsfind PRLD 10-K